View in EDS PDF Full Text

Neurotoxicidad inducida por ertapenem en pacientes de un hospital general.

Saved in:
Bibliographic Details
Title: Neurotoxicidad inducida por ertapenem en pacientes de un hospital general.
Alternate Title: Neurotoxicity Induced by Ertapenem in Patients of a General Hospital.
Authors: Cámara-Reyes, Ramón Rolando1 ramon.camara.03@gmail.com, Díaz-Carrión, Eddie Giampiere1, Zuñiga-Rosas, Marco Antonio1, Agurto-Lescano, Erika Cecilia1
Source: Revista Medica Herediana. ene-mar2026, Vol. 37 Issue 1, p21-26. 6p.
Subjects: SYNDROMES, RISK assessment, PUBLIC hospitals, NEUROTOXICOLOGY, PSYCHOMOTOR disorders, HEMOGLOBINS, ERTAPENEM, RETROSPECTIVE studies, BLOOD protein disorders, AGE distribution, DESCRIPTIVE statistics, HALLUCINATIONS, MEDICAL records, ACQUISITION of data, COGNITION disorders, DELIRIUM, CAUSALITY (Physics), KIDNEY diseases, ALBUMINS, COMORBIDITY, DISEASE risk factors, DISEASE complications, SYMPTOMS
Geographic Terms: PERU
Abstract (English): Objective: To describe the clinical characteristics and risk factors related to ertapenem-induced neurotoxicity in patients at a Peruvian hospital. Methods: A retrospective case series study was conducted, including seven cases recorded between 2023 and 2024. Neurotoxicity was defined as the presence of confusion, hallucinations, delirium, or other neurological symptoms that were resolved after discontinuing or substituting the antibiotic. Medical history, renal function, serum albumin, and hemoglobin levels were analyzed, and the Naranjo Scale was applied to assess the probability of causality. Results: Patients were over 60 years old with comorbidities such as hypertension (85.7%), chronic kidney disease (71.4%), and diabetes mellitus (57.14%). Neurological symptoms appeared on average 5.7 days after starting treatment, with confusion and psychomotor agitation being the most frequent. The average duration of ertapenem use was 7 days, and symptoms took 4.1 days to resolve after drug discontinuation. All cases were classified as "probable" according to the Naranjo Scale. Conclusion: Ertapenem-induced neurotoxicity was related to factors such as renal disease, hypoalbuminemia, and advanced age. Dose adjustment and monitoring of risk factors are recommended to minimize complications and optimize its use in clinical practice. [ABSTRACT FROM AUTHOR]
Abstract (Spanish): Objetivo: Describir las características clínicas y los factores de riesgo relacionados a la neurotoxicidad por el uso de ertapenem en pacientes de un hospital peruano. Material y métodos: Se realizó un estudio retrospectivo tipo serie de casos. Se incluyeron siete pacientes atendidos entre los años 2023 y 2024. La neurotoxicidad se definió como la presencia de confusión, alucinaciones, delirio y otros síntomas neurológicos que remitieron tras suspender o sustituir el antibiótico. Se analizaron antecedentes médicos, función renal, albúmina y hemoglobina séricas, además de la Escala de Naranjo para estimar la probabilidad de causalidad entre la reacción adversa y el uso de ertapenem. Resultados: Los pacientes fueron mayores de 60 años con comorbilidades como hipertensión arterial (85,7 %), enfermedad renal crónica (71,4 %) y diabetes mellitus (57,14 %). Los síntomas neurológicos aparecieron en promedio a los 5,7 días de iniciado el tratamiento, siendo la confusión y la agitación psicomotriz los más frecuentes. La duración promedio del uso de ertapenem fue de 7 días, y los síntomas tardaron 4,1 días en resolverse tras la suspensión del medicamento. Los casos fueron clasificados como "probable" según la Escala de Naranjo. Conclusión: La neurotoxicidad por ertapenem se asoció a factores como enfermedad renal, hipoalbuminemia y edad avanzada. Se recomienda ajustar las dosis y monitorear factores de riesgo para minimizar complicaciones y optimizar su uso en la práctica clínica. [ABSTRACT FROM AUTHOR]
Copyright of Revista Medica Herediana is the property of Universidad Peruana Cayetano Heredia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: MedicLatina
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: lth
DbLabel: MedicLatina
An: 193470533
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neurotoxicidad inducida por ertapenem en pacientes de un hospital general.
– Name: TitleAlt
  Label: Alternate Title
  Group: TiAlt
  Data: Neurotoxicity Induced by Ertapenem in Patients of a General Hospital.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Cámara-Reyes%2C+Ramón+Rolando%22">Cámara-Reyes, Ramón Rolando</searchLink><relatesTo>1</relatesTo><i> ramon.camara.03@gmail.com</i><br /><searchLink fieldCode="AR" term="%22Díaz-Carrión%2C+Eddie+Giampiere%22">Díaz-Carrión, Eddie Giampiere</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Zuñiga-Rosas%2C+Marco+Antonio%22">Zuñiga-Rosas, Marco Antonio</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Agurto-Lescano%2C+Erika+Cecilia%22">Agurto-Lescano, Erika Cecilia</searchLink><relatesTo>1</relatesTo>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Revista+Medica+Herediana%22">Revista Medica Herediana</searchLink>. ene-mar2026, Vol. 37 Issue 1, p21-26. 6p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22SYNDROMES%22">SYNDROMES</searchLink><br /><searchLink fieldCode="DE" term="%22RISK+assessment%22">RISK assessment</searchLink><br /><searchLink fieldCode="DE" term="%22PUBLIC+hospitals%22">PUBLIC hospitals</searchLink><br /><searchLink fieldCode="DE" term="%22NEUROTOXICOLOGY%22">NEUROTOXICOLOGY</searchLink><br /><searchLink fieldCode="DE" term="%22PSYCHOMOTOR+disorders%22">PSYCHOMOTOR disorders</searchLink><br /><searchLink fieldCode="DE" term="%22HEMOGLOBINS%22">HEMOGLOBINS</searchLink><br /><searchLink fieldCode="DE" term="%22ERTAPENEM%22">ERTAPENEM</searchLink><br /><searchLink fieldCode="DE" term="%22RETROSPECTIVE+studies%22">RETROSPECTIVE studies</searchLink><br /><searchLink fieldCode="DE" term="%22BLOOD+protein+disorders%22">BLOOD protein disorders</searchLink><br /><searchLink fieldCode="DE" term="%22AGE+distribution%22">AGE distribution</searchLink><br /><searchLink fieldCode="DE" term="%22DESCRIPTIVE+statistics%22">DESCRIPTIVE statistics</searchLink><br /><searchLink fieldCode="DE" term="%22HALLUCINATIONS%22">HALLUCINATIONS</searchLink><br /><searchLink fieldCode="DE" term="%22MEDICAL+records%22">MEDICAL records</searchLink><br /><searchLink fieldCode="DE" term="%22ACQUISITION+of+data%22">ACQUISITION of data</searchLink><br /><searchLink fieldCode="DE" term="%22COGNITION+disorders%22">COGNITION disorders</searchLink><br /><searchLink fieldCode="DE" term="%22DELIRIUM%22">DELIRIUM</searchLink><br /><searchLink fieldCode="DE" term="%22CAUSALITY+%28Physics%29%22">CAUSALITY (Physics)</searchLink><br /><searchLink fieldCode="DE" term="%22KIDNEY+diseases%22">KIDNEY diseases</searchLink><br /><searchLink fieldCode="DE" term="%22ALBUMINS%22">ALBUMINS</searchLink><br /><searchLink fieldCode="DE" term="%22COMORBIDITY%22">COMORBIDITY</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+risk+factors%22">DISEASE risk factors</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+complications%22">DISEASE complications</searchLink><br /><searchLink fieldCode="DE" term="%22SYMPTOMS%22">SYMPTOMS</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22PERU%22">PERU</searchLink>
– Name: Abstract
  Label: Abstract (English)
  Group: Ab
  Data: Objective: To describe the clinical characteristics and risk factors related to ertapenem-induced neurotoxicity in patients at a Peruvian hospital. Methods: A retrospective case series study was conducted, including seven cases recorded between 2023 and 2024. Neurotoxicity was defined as the presence of confusion, hallucinations, delirium, or other neurological symptoms that were resolved after discontinuing or substituting the antibiotic. Medical history, renal function, serum albumin, and hemoglobin levels were analyzed, and the Naranjo Scale was applied to assess the probability of causality. Results: Patients were over 60 years old with comorbidities such as hypertension (85.7%), chronic kidney disease (71.4%), and diabetes mellitus (57.14%). Neurological symptoms appeared on average 5.7 days after starting treatment, with confusion and psychomotor agitation being the most frequent. The average duration of ertapenem use was 7 days, and symptoms took 4.1 days to resolve after drug discontinuation. All cases were classified as "probable" according to the Naranjo Scale. Conclusion: Ertapenem-induced neurotoxicity was related to factors such as renal disease, hypoalbuminemia, and advanced age. Dose adjustment and monitoring of risk factors are recommended to minimize complications and optimize its use in clinical practice. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label: Abstract (Spanish)
  Group: Ab
  Data: Objetivo: Describir las características clínicas y los factores de riesgo relacionados a la neurotoxicidad por el uso de ertapenem en pacientes de un hospital peruano. Material y métodos: Se realizó un estudio retrospectivo tipo serie de casos. Se incluyeron siete pacientes atendidos entre los años 2023 y 2024. La neurotoxicidad se definió como la presencia de confusión, alucinaciones, delirio y otros síntomas neurológicos que remitieron tras suspender o sustituir el antibiótico. Se analizaron antecedentes médicos, función renal, albúmina y hemoglobina séricas, además de la Escala de Naranjo para estimar la probabilidad de causalidad entre la reacción adversa y el uso de ertapenem. Resultados: Los pacientes fueron mayores de 60 años con comorbilidades como hipertensión arterial (85,7 %), enfermedad renal crónica (71,4 %) y diabetes mellitus (57,14 %). Los síntomas neurológicos aparecieron en promedio a los 5,7 días de iniciado el tratamiento, siendo la confusión y la agitación psicomotriz los más frecuentes. La duración promedio del uso de ertapenem fue de 7 días, y los síntomas tardaron 4,1 días en resolverse tras la suspensión del medicamento. Los casos fueron clasificados como "probable" según la Escala de Naranjo. Conclusión: La neurotoxicidad por ertapenem se asoció a factores como enfermedad renal, hipoalbuminemia y edad avanzada. Se recomienda ajustar las dosis y monitorear factores de riesgo para minimizar complicaciones y optimizar su uso en la práctica clínica. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Revista Medica Herediana is the property of Universidad Peruana Cayetano Heredia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=193470533
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.20453/rmh.v37i1.6748
    Languages:
      – Code: spa
        Text: Spanish
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 21
    Subjects:
      – SubjectFull: SYNDROMES
        Type: general
      – SubjectFull: RISK assessment
        Type: general
      – SubjectFull: PUBLIC hospitals
        Type: general
      – SubjectFull: NEUROTOXICOLOGY
        Type: general
      – SubjectFull: PSYCHOMOTOR disorders
        Type: general
      – SubjectFull: HEMOGLOBINS
        Type: general
      – SubjectFull: ERTAPENEM
        Type: general
      – SubjectFull: RETROSPECTIVE studies
        Type: general
      – SubjectFull: BLOOD protein disorders
        Type: general
      – SubjectFull: AGE distribution
        Type: general
      – SubjectFull: DESCRIPTIVE statistics
        Type: general
      – SubjectFull: HALLUCINATIONS
        Type: general
      – SubjectFull: MEDICAL records
        Type: general
      – SubjectFull: ACQUISITION of data
        Type: general
      – SubjectFull: COGNITION disorders
        Type: general
      – SubjectFull: DELIRIUM
        Type: general
      – SubjectFull: CAUSALITY (Physics)
        Type: general
      – SubjectFull: KIDNEY diseases
        Type: general
      – SubjectFull: ALBUMINS
        Type: general
      – SubjectFull: COMORBIDITY
        Type: general
      – SubjectFull: DISEASE risk factors
        Type: general
      – SubjectFull: DISEASE complications
        Type: general
      – SubjectFull: SYMPTOMS
        Type: general
      – SubjectFull: PERU
        Type: general
    Titles:
      – TitleFull: Neurotoxicidad inducida por ertapenem en pacientes de un hospital general.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cámara-Reyes, Ramón Rolando
      – PersonEntity:
          Name:
            NameFull: Díaz-Carrión, Eddie Giampiere
      – PersonEntity:
          Name:
            NameFull: Zuñiga-Rosas, Marco Antonio
      – PersonEntity:
          Name:
            NameFull: Agurto-Lescano, Erika Cecilia
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: ene-mar2026
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 1018130X
          Numbering:
            – Type: volume
              Value: 37
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Revista Medica Herediana
              Type: main
ResultId 1